London, England -- (SBWire) -- 05/20/2019 --Visiongain has launched a new pharma report mRNA Vaccines and Therapeutics Market Forecast 2019-2029: Standardized Therapeutic Cancer mRNA Vaccines, Individualized Therapeutic Cancer mRNA Vaccines, Therapeutic Infectious Disease mRNA Vaccines, mRNA Therapeutic for Other Diseases, Bioengineered Vaccine, Gene Transcription, Monoclonal Antibody,Gene Therapy and Cell Therapy.
mRNA-based drugs have emerged as a highly attractive new class of biologics that encodes any protein of interest directly in vivo. The last two decades have been crucial in generating interest in various RNA based technologies. Clinical and preclinical trials in the field have led to positive responses facilitating increasing funding, investment by major pharmaceutical and biopharmaceutical companies. Clinical trials have proven that mRNA vaccines provide long lasting immune responses and are safe in animal and human models.
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on 020 7549 9987
The lead analyst of the report commented "The major drivers supporting the growth of the mRNA Vaccines and Therapeutics Market are rising adoption of personalized medicine for effective treatment, advantages offered by mRNA-based products, and rising funding by pharmaceutical companies and government organizations. Effective and safe delivery remains a major challenge despite the potential of RNA therapy. High cost of development and stringent process of regulatory approvals might also restrain the mRNA vaccines and therapeutics market."
Download free report sample pages
Leading companies featured in the report include Argos Therapeutics, Inc., BioNTech AG. CureVac AG, eTheRNA Immunotherapies, ethris GmbH, In-Cell-Art, Moderna Therapeutics, Sangamo Therapeutics, Inc., Tiba Biotech, Translate Bio and Inc.
Related reports:
Global Cancer Immunotherapy Market Forecast 2019-2029
Global Vaccine Contract Manufacturing Market Report 2019-2029
For more pharma reports, visit our website
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on 020 7549 9987
About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Global mRNA Vaccines and Therapeutics Market Set to Grow to $5.5bn by 2024, According to Visiongain